Cogent Biosciences is a biotechnology company focused on developing novel precision therapies for genetically defined diseases. The Company’s lead program, bezuclastinib, is a potential best-in-class KIT mutant inhibitor in late-stage clinical trials in patients with Systemic Mastocytosis (SM) and Gastrointestinal Stromal Tumors (GIST). In addition, the Cogent Research Team is developing a pipeline of novel preclinical therapies targeting ErbB2, FGFR2, PI3Ka and KRAS.